FDA Approves First Oral GLP-1 for Weight Loss, Ending the Era of Injection-Only Therapy

Eli Lilly's orforglipron, branded as Foundayo, received FDA approval on April 1 as the first daily pill for obesity treatment—a seismic shift for the 40 million Americans currently on injectable GLP-1 medications. The drug showed 7–9% weight loss in trials, less than injectable tirzepatide's 20%, but analysts say convenience could drive adoption past injectables within two years.

By The GLP Truth Staff · April 8, 2026 · 8 min read

FDA & Regulation

FDA Issues 30 Warning Letters in Largest-Ever Crackdown on Compounded GLP-1 Sellers

The agency declared semaglutide and tirzepatide shortages officially resolved, then moved swiftly against telehealth companies still marketing compounded versions. Patients on compounded medications face immediate supply disruption.

March 2026 · 6 min read

Market & Pricing

Novo Nordisk Slashes Wegovy and Ozempic List Prices by Up to 50%

The Danish pharmaceutical giant announced its biggest-ever U.S. price reduction, bringing Wegovy's list price to approximately $675/month. The move comes as Medicare negotiates $274/month coverage under the Inflation Reduction Act, effective January 2027.

Feb 24, 2026 · CNBC · 5 min read

Clinical Science

The Muscle Crisis: 25–40% of GLP-1 Weight Loss Is Lean Mass, Not Fat

A growing body of evidence shows rapid weight loss on semaglutide and tirzepatide comes at a hidden cost. New research in Obesity Reviews quantifies what physicians have warned about for years: without resistance training and protein protocols, patients are losing the tissue their metabolism depends on.

Featured Investigation · 12 min read

Clinical Trial

SURMOUNT-5: Tirzepatide Outperforms Semaglutide in First Head-to-Head Trial

The long-awaited direct comparison showed tirzepatide producing 20.2% body weight loss versus 13.7% for semaglutide over 72 weeks. The dual GIP/GLP-1 mechanism appears to deliver meaningfully superior outcomes across every measured endpoint.

NEJM · 2026 · 7 min read

Physician-Led GLP-1 Programs · From $99/mo

Your Prescription Came Without a Protocol.
We Built One.

Labs. Protein targets. Resistance training Rx. Supplement stacks. Monthly physician follow-up. The complete system that telehealth startups skip—starting at $99/month.

Start Your Program →

Regulation

States Move to Ban Compounded Semaglutide as FDA Enforcement Widens

At least six states have introduced legislation restricting 503A compounding pharmacies from producing GLP-1 receptor agonists. The legal landscape is shifting faster than most patients realize.

April 2026 · 4 min read

Insurance

Medicare GLP-1 Coverage Goes Live: What 7 Million Seniors Need to Know

The Inflation Reduction Act's anti-obesity medication provision takes effect, covering semaglutide at $274/month for Medicare Part D enrollees. CMS expects 3.4 million new prescriptions in the first year, with prior authorization requirements varying by plan.

CMS · March 2026 · 5 min read

Patient Safety

The Nutrient Gap: 90% of GLP-1 Patients Are Deficient and Don't Know It

Severe appetite suppression reduces caloric intake by 30–40%—and micronutrient intake drops with it. Vitamin D, B12, magnesium, and potassium deficiencies are near-universal among long-term GLP-1 users. Only 20% receive dietitian referrals.

Investigation · 10 min read

Drug Pipeline

Retatrutide Phase 3 Data Expected by Year-End: The Triple Agonist That Could Change Everything

Eli Lilly's triple-receptor agonist (GIP + GLP-1 + glucagon) showed 24%+ weight loss in Phase 2—the highest of any obesity drug in history. Phase 3 enrollment is complete with results anticipated Q4 2026.

Eli Lilly · Pipeline Watch · 4 min read

Featured · Teleios Health

What They Lied to You
About GLP-1s

Up to 40% of what you lose is muscle. You regain weight within 1.7 years of stopping. 90%+ are nutrient deficient. A board-certified physician's report on what the industry hides.

Read the Free Report →

Analysis & Opinion

A Prescription Is Not a Protocol: Why the GLP-1 Standard of Care Must Change
Dr. Ana Lisa Carr, MD · Lion MD Medical Review Board
The Compounding Loophole Is Closed. Now What?
The GLP Truth Editorial Board
Oral vs. Injectable: Why Convenience May Matter More Than Efficacy for Population Health
The GLP Truth Staff
The SELECT Trial Changed How Physicians Think About Obesity. It Should Change How You Think Too.
Dr. Kelly Tenbrink, MD · Lion MD Medical Review Board

• WHO classified obesity as a chronic disease requiring long-term pharmacotherapy in landmark December 2025 guidance, changing reimbursement patterns globally.
• Eli Lilly's Foundayo (orforglipron) approved April 1 as first oral GLP-1 for obesity. Daily pill at $149/mo list price.
• FDA sent 30 warning letters to telehealth companies including Beluga Health and OpenLoop for illegal compounded GLP-1 marketing.
• SELECT trial confirmed 20% reduction in heart attacks, strokes, and cardiovascular death in semaglutide users independent of weight loss.
• SURMOUNT-5 head-to-head data shows tirzepatide beats semaglutide: 20.2% vs 13.7% weight loss over 72 weeks.
• Compounding pharmacy stocks dropped 40–60% after FDA shortage resolution announcement.
• Novo Nordisk cut list prices up to 50% on Wegovy ($675/mo) and Ozempic. Effective immediately.